cbi delisted from nasdaq, page-29

very quiet here.

Tim is looking after his company very nicely.

Director Related Transactions
'On the 7th June 2009 the company signed a management services agreement with Fusion Life Sciences Pty Ltd, a company of which Mr Tim Boyd is director. The agreement was tor the provision of services in respect of a corporate restructure A payment of $30,000 was made in June 2009 far three months' services. The fee structure is for $10,000 per month for a minimum of 4 months. The issue of 2 million BOS shares with a Reverse Merger Success Fee of $150,000. Fifty percent of this success fee may be converted to equity in Biosignal at the election of Fusion Lifesciences at a price per share of $0.01 5 on closing of a Successful reverse merger transaction.'

````

The inference from the report is that the Conoco trial was not successful. This is not stated explicitly, just that there were no late stage negotiations [what about early stage?] and there is no development of a commercial agreement. But how did the trials go? It must be remembered that CBTE is buying this IP. They are not being clear where they see the value. Maybe they will be more clear after the sale.